Core Viewpoint - The innovative drug concept stocks in Hong Kong have strengthened, particularly Heptares Therapeutics (2142.HK), which saw its stock price rise nearly 13% to a historical high of 14.35 HKD following the announcement of impressive financial results [1] Financial Performance - Heptares Therapeutics reported total revenue of approximately 725 million HKD for the first half of 2025, representing a year-on-year increase of 327% [1] - The company's profit reached approximately 523 million HKD, marking a year-on-year growth of 51 times [1] - Cash reserves are robust, amounting to approximately 2.291 billion HKD, which is a 92% increase compared to the end of the previous year [1] Fundraising and Development Plans - Heptares Therapeutics announced plans to raise over 500 million HKD through a share placement at a price of 11.5 HKD per share [1] - The funds will be used to expand the research and development of innovative drug assets and to advance the clinical trials of existing pipeline drug assets [1]
港股异动丨盈利飙升51倍，和铂医药大涨近13%，创历史新高